Registry Enrollment for Alzheimer’s Drug Coverage Won’t Help Much

11. July 2023 Health 0
Registry Enrollment for Alzheimer’s Drug Coverage Won’t Help Much

(MedPage Today) — The Medicare program announced it will cover much of the substantial costs of lecanemab (Leqembi), the now fully FDA approved monoclonal antibody for Alzheimer’s disease, but only for patients who have been entered into a registry…

Powered by WPeMatico